Drug intelligence / Profile preview

Bifidobacterium longum APC1472

Development stage: Preclinical
Lead developer: APC Microbiome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium longum APC1472 is an investigational live biotherapeutic product (probiotic) being developed for the management of obesity and related metabolic conditions. It is a specific strain of *Bifidobacterium longum* that was initially selected for its ability to attenuate ghrelin receptor signaling in vitro. [1] Preclinical studies in mice showed that it reduced body weight gain, fat accumulation, and improved glucose tolerance. [3] A clinical study in overweight and obese humans (NCT04042181) did not show a significant effect on the primary endpoint of BMI, but did demonstrate a statistically significant reduction in fasting blood glucose levels compared to placebo. [1, 3] In a sub-analysis of obese participants, it also increased active ghrelin levels and reduced the cortisol awakening response, suggesting modulation of the ghrelinergic system and the hypothalamic-pituitary-adrenal (HPA) axis. [2, 5]

Targets

GHSR (Growth hormone secretagogue receptor)

Beyond the preview

Go deeper on Bifidobacterium longum APC1472.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium longum APC1472.

Explore the full profile